Literature DB >> 26574990

Metastasis to the Glans Penis: An Unusual Site of Rectal Cancer Recurrence.

Beatriz Nunes1, Margarida Matias2, António Alves3, Marília Jorge1.   

Abstract

Secondary malignancy of the penis is a rare clinical condition, often associated with disseminated genitourinary malignancies. The prognosis is poor and the treatment options include penectomy, local surgical excision, radiation therapy, chemotherapy and supportive therapy. Neither of these therapeutic options lead to superior treatment outcomes in the literature. The authors report the case of a 66 year-old man with a metastasis to the glans penis from a rectal adenocarcinoma, diagnosed two years after radical treatment for primary disease. The patient underwent palliative treatment with radiotherapy and chemotherapy, remaining asymptomatic and disease-free at one year follow-up. Close follow-up of patients with history of rectal adenocarcinoma is very important. Radiochemotherapy is a feasible and effective therapeutic option for penile metastasis, addressing both disease control and symptomatic improvement.

Entities:  

Mesh:

Year:  2015        PMID: 26574990     DOI: 10.20344/amp.5775

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  3 in total

1.  A Case Report and Review of the Literature of Penile Metastasis From Rectal Cancer.

Authors:  Azuolas Kaminskas; Ausvydas Patasius; Marius Kincius; Virginijus Sapoka; Rytis Zilevicius; Aušra Garnelytė; Audrius Dulskas
Journal:  Front Surg       Date:  2022-05-09

2.  Penile Metastasis from Rectal Carcinoma: Case Report and Review of the Literature.

Authors:  Justas Kuliavas; Audrius Dulskas; Julius Drachneris; Edita Miseikyte-Kaubriene; Narimantas E Samalavicius
Journal:  Visc Med       Date:  2018-07-31

3.  Penile metastasis in rectal cancer with pathologic complete response after neoadjuvant chemoradiotherapy: The first case report and literature review.

Authors:  Taek-Gu Lee; Seung-Myoung Son; Myung Jo Kim; Sang-Jeon Lee
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.